Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2012-08, Vol.13 (8), p.766-767
Hauptverfasser:	Doss, Sally, Robertson, Janet, Adam, Jane
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - economics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Aromatase Inhibitors - administration & dosage Biomarkers, Tumor - antagonists & inhibitors Biomarkers, Tumor - metabolism Breast Neoplasms - drug therapy Breast Neoplasms - economics Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - secondary Cost-Benefit Analysis Drug Costs Female Guideline Adherence Hematology, Oncology and Palliative Medicine Humans Practice Guidelines as Topic Quality-Adjusted Life Years Quinazolines - administration & dosage Receptor, ErbB-2 - antagonists & inhibitors Receptor, ErbB-2 - metabolism Trastuzumab Treatment Outcome United Kingdom Up-Regulation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!